New antibody for dermatitis set to move into late-stage trials

Shares in Singapore and California, USA-based biotech ASLAN Pharmaceuticals (Nasdaq: ASLN) have fallen by a quarter as traders pore over mid-stage data for lead candidate eblasakimab.

The top-line results show the Phase IIb dose-ranging study met its primary endpoint, a measure of efficacy in treating adults with moderate-to-severe atopic dermatitis (AD).

However, the data also show a high response from the placebo arm, a factor which appears to have confused the picture somewhat.